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2 cycles of chemotherapy. Common non-hematologic toxicities of all 
grades during consolidation chemotherapy were anorexia(45%), alope-
cia(41%), asthenia(35%), and esophagitis(41%). Hematologic toxicities 
were mild. Although Grade 3-4 neutropenia occurred in 5 cycles out of 
65 cycles, there was no treatment-related mortality 
Conclusions: These results suggest that CCRT with weekly docetaxel 
and cisplatin is feasible and consolidation chemotherapy with same 
agents after CCRT is also well tolerated. Further data will be updated 
on presentation.
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Background: Concurrent chemoradiotherapy (chemoRT) is the pre-
ferred treatment for patients with unresectable stage III NSCLC. Lim-
ited safety information is available on the use of concurrent docetaxel, 
carboplatin and thoracic RT. We report the safety information on the 
initial 100 patients (pts) treated with this chemoRT as part of an ongo-
ing US randomized web-based phase III trial (D0410) evaluating the 
role of erlotinib/placebo following this concurrent chemoRT treatment. 
The sample size is 400 pts and the primary endpoint is progression-free 
survival.
Methods: Pts with unresectable pathologically conﬁrmed stage III 
NSCLC are randomized to receive either erlotinib 150 mg or placebo 
orally daily for 2 years following concurrent chemoRT with docetaxel 
20 mg/m2, carboplatin AUC=2 intravenously weekly for 6 wks with 
thoracic RT of at least 61 Gy in 33 fractions over 6.5 weeks. The 
planned total lung volume exceeding 20 Gy (V20) was less than 32%. 
Only the chemoradiation safety information is being reported. This data 
was reviewed by an independent safety and data monitoring committee.
Results: Pt characteristics; 59% males, median age 69 years (range 38 
to 86), 21% adenocarcinoma, 48% squamous cell, 94% ECOG PS0-1, 
49% stage IIIA, 15% weight loss ≥ 10%. Of 600 planned chemotherapy 
treatments, 500 were administered (93 wk 1, 86 wk 2, 83 wk 3, 82 wk 4, 
80 wk 5, 76 wk 6). There were 27 chemotherapy dose reductions; most 
commonly for esophagitis (8), neutropenia (5), renal dysfunction (3), hy-
persensitivity (2). There were no treatment-related deaths. There were 28 
grade 3 and 3 grade 4 treatment-related adverse events. The most com-
mon grade 3/4 events were esophagitis (7), fatigue (3), dysphagis (2), 
odynophagia (2), neutropenia (1), thrombocytopenia (1), dematitis (1).
Conclusions: This concurrent chemoradiation regimen appears to be 
safe. Enrollment to the phase III trial continues. There is a planned 
interim efﬁcacy evaluation at 150 events (deaths or disease progres-
sion). Funded in part by Sanoﬁ-Aventis, Genentech, and OSI Pharma-
ceuticals.
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Purpose and Objective(s): To assess the incidence and severity of 
acute esophageal reactions from concurrent chemotherapy and 3-di-
mensional proton beam therapy (PBT) in the context of previous results 
with concurrent chemotherapy and 3-dimensional photon therapy (XT) 
for NSCLC.
Materials and Methods: Twenty-ﬁve consecutive patients with NSC-
CL (stages IIB [1], IIIA [8], IIIB [8], IV [2], post-operative recurrent 
[6], underwent PBT and concurrent chemotherapy with curative intent 
on IRB approved protocols. Chemotherapy was platinum-based in all 
patients, most frequently carboplatin/paclitaxel (16 patients). There 
were 16 males/9 females ranging in age from 49 to 81 years (median 
67 years). Histopathologic diagnosis was squamous cell carcinoma in 9 
and non-squamous in 16 patients. All patients were evaluable for acute 
(< or = 90 days from ﬁrst treatment) reactions. Toxicity was based on 
NCI common toxicity criteria vs. 3.0. XT comparisons were based on 
published data from our institution (215 patients) (Wei X et al, Int J 
Radiat Oncol Biol Phys 2006)
Results: Total doses with PBT ranged from 63 cobalt-gray equivalent 
(CGE) (using RBE of 1.1 vs. cobalt gamma rays) to 74 CGE (60-69.6 
Gy with XT) in 33 to 37 fractions (30-58 fractions with XT). The 
median total dose was 74 CGE vs. 63 Gy for XT. Acute esophageal 
reactions were observed in 60% of PBT patients (200 of 215/93% with 
XT). Seven (28%) of patients had grade 2 esophageal reactions (97 of 
215/45.1% with XT). Four (16%) of patients had grade 3 esophageal 
reactions (43 of 215/20.0% with XT). No patient had a grade 4 reaction 
(1of 215/0.5% with XT).
Conclusions: Proton beam therapy permitted higher total doses (17%+) 
with concurrent chemotherapy yet were associated with reduced 
esophageal reactions compared with 3-dimensional conformal photon 
therapy.
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